Attorney's Locket No.: 10634-005001 / UCHI 848

Applicant: Ching Song al. Serial No.: 10/072,128 Filed: February 8, 2002

Page : 2

with -NH-, -N(alkyl)-, -O-, -S-, -SO-, -SO<sub>2</sub>-, -O-SO<sub>2</sub>-, -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-O-, -O-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-, and further optionally substituted with hydroxy, halo, amino, carboxyl, sulfonic acid, or -O-sulfonic acid; R<sub>4</sub> is hydrogen, hydroxy, amino, carboxyl, halo, sulfonic acid, -O-sulfonic acid, alkyl that is optionally inserted with -NH-, -N(alkyl)-, -O-, -S-, -SO-, -SO<sub>2</sub>-, -O-SO<sub>2</sub>-, -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-O-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-, and further optionally substituted with hydroxy, halo, amino, carboxyl, sulfonic acid, or -O-sulfonic acid; or R<sub>4</sub> together with R<sub>4</sub>· is oxo;

 $R_{4'}$  is hydrogen, hydroxy, amino, carboxyl, halo, sulfonic acid, -O-sulfonic acid, alkyl that is optionally inserted with -NH-, -N(alkyl)-, -O-, -S-, -SO-, -SO<sub>2</sub>-, -O-SO<sub>2</sub>-, -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-O-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-, and further optionally substituted with hydroxy, halo, amino, carboxyl, sulfonic acid, or -O-sulfonic acid; or  $R_{4'}$  together with  $R_4$  is oxo;

each of  $R_{17}$ , and  $R_{17}$ , independently, is hydrogen, hydroxy, amino, carboxyl, halo, sulfonic acid, -O-sulfonic acid, or alkyl that is optionally inserted with -NH-, -N(alkyl)-, -O-, -S-, -SO-, -SO<sub>2</sub>-, -O-SO<sub>2</sub>-, -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, CO-, -CO-O-, -O-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-, and further optionally substituted with hydroxy, halo, amino, carboxyl, sulfonic acid, or -O-sulfonic acid;

R<sub>3</sub> is X-Y-, wherein X is hydrogen, amino, carboxyl, halo, sulfonic acid, -O-sulfonic acid, or alkyl; Y is -S-, -NH-, -N(alkyl)-, -SO-, -SO<sub>2</sub>-, -O-SO<sub>2</sub>-, -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -O-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-;

 $R_5$  and  $R_6$ , together, are -O-; or  $R_5$  and  $R_6$ , together, are a double bond between C-5 and C-6, and  $R_7$  is oxo;

each of R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub>, R<sub>13</sub>, and R<sub>14</sub>, independently, is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxy, hydroxy, or amino; and n is 0, 1, or 2.

Sub-Eint.


A'

Attorney's scket No.: 10634-005001 / UCHI 848

Applicant: Ching Song al. Serial No.: 10/072,128 Filed: February 8, 2002

Page: 3

33. A pharmaceutical composition comprising a compound of formula (1):



wherein:

each of R<sub>1</sub>, R<sub>2</sub>, R<sub>7</sub>, R<sub>11</sub>, R<sub>12</sub>, R<sub>15</sub>, and R<sub>16</sub>, independently, is hydrogen, hydroxy, amino, carboxyl, oxo, halo, sulfonic acid, -Q-sulfonic acid, or alkyl that is optionally inserted with - NH-, -N(alkyl)-, -O-, -S-, -SO-, -SO<sub>2</sub>-, -O-SO<sub>2</sub>-, -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-O-, -O-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-, and further optionally substituted with hydroxy, halo, amino, carboxyl, sulfonic acid, or -O-sulfonic acid;

 $R_4$  is hydrogen, hydroxy, amino, carboxyl, halo, sulfonic acid, -O-sulfonic acid, alkyl that is optionally inserted with -NH-, -N(alkyl)-, -O-, -SO-, -SO-, -SO2-, -O-SO2-, -SO2-O-, -SO3-O-, -CO-, -CO-O-, -O-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-, and further optionally substituted with hydroxy, halo, amino, carboxyl, sulfonic acid, or -O-sulfonic acid; or  $R_4$  together with  $R_4$  is oxo;

 $R_{4'}$  is hydrogen, hydroxy, amino, carboxyl, halo, sulfonic acid, -O-sulfonic acid, alkyl that is optionally inserted with -NH-, -N(alkyl)-, -O-, -SO-, -SO<sub>2</sub>-, -O-SO<sub>2</sub>-, -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-O-, -O-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-, and further optionally substituted with hydroxy, halo, amino, carboxyl, sulfonic acid, or -O-sulfonic acid; or  $R_{4'}$  together with  $R_4$  is oxo;

each of  $R_{17}$ , and  $R_{17}$ , independently, is hydrogen, hydroxy, amino, carboxyl, halo, sulfonic acid, -O-sulfonic acid, or alkyl that is optionally inserted with -NH-, -N(alkyl)-, -O-, -S-, -SO-, -SO<sub>2</sub>-, -O-SO<sub>2</sub>-, -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-O-, -O-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-, and further optionally substituted with hydroxy, halo, amino, carboxyl, sulfonic acid, or -O-sulfonic acid;

()



Applicant: Ching Song et al Serial No.: 10/072,128

Filed : February 8, 2002

Page: 4

R<sub>3</sub> is X-Y-, wherein X is hydrogen, amino, carboxyl, halo, sulfonic acid, -O-sulfonic acid, or

alkyl; Y is -S-, -NH-, -N(alkyl)-, -SO-, -SO<sub>2</sub>-, -O-SO<sub>2</sub>-, -SO<sub>2</sub>-O-, -SO<sub>3</sub>-O-, -CO-, -CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-;

R<sub>5</sub> and R<sub>6</sub>, together, are -O-; or R<sub>5</sub> and R<sub>6</sub>, together, are a double bond between C-5 and C-6,

Attorney's Docket No.: 10634-005001 / UCHI 848

and R7 is oxo;

each of R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub>, R<sub>13</sub>, and R<sub>14</sub>, independently, is hydrogen, alkyl, haloalkyl, hydroxyalkyl,

alkoxy, hydroxy, or amino; and

n is 0, 1, or 2;

and a pharmaceutically acceptable carrier .--

Aub Cont.